Skip to content

Study · Case report or series · n = 1 · 2024

3 results

Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.

Le Guiniec M, Borel AL

European journal of clinical nutrition27 May 2024

PMID38802605 (opens in a new tab)DOI10.1038/s41430-024-01450-8 (opens in a new tab)PepBankPUB-38802605
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 24-year-old woman with holoprosencephaly and class III obesity, body weight fell after one year of semaglutide.

    In plain wordsIn one woman with holoprosencephaly and severe obesity, body weight fell after one year of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change after one year
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg/week · 1 yearAs given in this study (human).

    Measurements

    Body weight
    115.3 to 94.3 kg
    before and after one year
    Total body weight loss
    18%
    one year

    Source sentences

    Summary
    Her body weight decreased from 115.3 to 94.3 kg after one-year (18% of total body weight loss).
    1 context sentence
    Summary · context
    We present a case of a 24 year-old woman with holoprosencephaly and class III obesity who was treated by 2.4 mg/week SEMAGLUTIDE.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with holoprosencephaly and class III obesity, semaglutide was accompanied by a marked reduction in self- and hetero-aggressive behaviour when she saw food.

    In plain wordsIn one woman with holoprosencephaly, aggressive behaviour around food was much reduced while she took semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseSelf- and hetero-aggressive behaviour when exposed to food
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2.4 mg/weekAs given in this study (human).

    Source sentences

    Summary
    In addition, she presented a marked reduction in self- and hetero-aggressive behaviour when exposed to the sight of food.
    1 context sentence
    Summary · context
    We present a case of a 24 year-old woman with holoprosencephaly and class III obesity who was treated by 2.4 mg/week SEMAGLUTIDE.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with holoprosencephaly and class III obesity, semaglutide was well tolerated except for a few episodes of vomiting after eating palatable food too quickly.

    In plain wordsIn one woman, semaglutide was well tolerated apart from a few episodes of vomiting after eating tasty food too fast.

    Peptide
    Semaglutide
    Outcome
    Not applicableVomiting when eating palatable food quickly
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg/weekAs given in this study (human).

    Source sentences

    Summary
    The treatment was well tolerated, with the exception of a few vomiting when eating palatable food too quickly.
    1 context sentence
    Summary · context
    We present a case of a 24 year-old woman with holoprosencephaly and class III obesity who was treated by 2.4 mg/week SEMAGLUTIDE.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.